BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 16545584)

  • 1. Development and characterization of LLC-PK1 cells containing Sprague-Dawley rat Abcb1a (Mdr1a): comparison of rat P-glycoprotein transport to human and mouse.
    Booth-Genthe CL; Louie SW; Carlini EJ; Li B; Leake BF; Eisenhandler R; Hochman JH; Mei Q; Kim RB; Rushmore TH; Yamazaki M
    J Pharmacol Toxicol Methods; 2006; 54(1):78-89. PubMed ID: 16545584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Establishment and characterization of the transformants stably-expressing MDR1 derived from various animal species in LLC-PK1.
    Takeuchi T; Yoshitomi S; Higuchi T; Ikemoto K; Niwa S; Ebihara T; Katoh M; Yokoi T; Asahi S
    Pharm Res; 2006 Jul; 23(7):1460-72. PubMed ID: 16779700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Kinetic analyses for species differences in P-glycoprotein-mediated drug transport.
    Katoh M; Suzuyama N; Takeuchi T; Yoshitomi S; Asahi S; Yokoi T
    J Pharm Sci; 2006 Dec; 95(12):2673-83. PubMed ID: 16892207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood-brain barrier (BBB) pharmacoproteomics: reconstruction of in vivo brain distribution of 11 P-glycoprotein substrates based on the BBB transporter protein concentration, in vitro intrinsic transport activity, and unbound fraction in plasma and brain in mice.
    Uchida Y; Ohtsuki S; Kamiie J; Terasaki T
    J Pharmacol Exp Ther; 2011 Nov; 339(2):579-88. PubMed ID: 21828264
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitative investigation of the role of breast cancer resistance protein (Bcrp/Abcg2) in limiting brain and testis penetration of xenobiotic compounds.
    Enokizono J; Kusuhara H; Ose A; Schinkel AH; Sugiyama Y
    Drug Metab Dispos; 2008 Jun; 36(6):995-1002. PubMed ID: 18322075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of phosphine complexes of technetium(III) as transport substrates of the multidrug resistance P-glycoprotein and functional markers of P-glycoprotein at the blood-brain barrier.
    Luker GD; Rao VV; Crankshaw CL; Dahlheimer J; Piwnica-Worms D
    Biochemistry; 1997 Nov; 36(46):14218-27. PubMed ID: 9369495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in the transport of the antiepileptic drugs phenytoin, levetiracetam and carbamazepine by human and mouse P-glycoprotein.
    Baltes S; Gastens AM; Fedrowitz M; Potschka H; Kaever V; Löscher W
    Neuropharmacology; 2007 Feb; 52(2):333-46. PubMed ID: 17045309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar.
    Tang SC; Nguyen LN; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Int J Cancer; 2014 Mar; 134(6):1484-94. PubMed ID: 24037730
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abcb1a (P-glycoprotein) limits brain exposure of the anticancer drug candidate seliciclib in vivo in adult mice.
    Erdő F; Nagy I; Tóth B; Bui A; Molnár É; Tímár Z; Magnan R; Krajcsi P
    Brain Res Bull; 2017 Jun; 132():232-236. PubMed ID: 28629814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytofluorimetric analysis of a renal tubular cell line and its resistant counterpart.
    Rosati A; Decorti G; Klugmann FB; Candussio L; Granzotto M; Melato M; Giraldi T
    Anticancer Res; 2000; 20(5B):3403-10. PubMed ID: 11131640
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro substrate identification studies for p-glycoprotein-mediated transport: species difference and predictability of in vivo results.
    Yamazaki M; Neway WE; Ohe T; Chen I; Rowe JF; Hochman JH; Chiba M; Lin JH
    J Pharmacol Exp Ther; 2001 Mar; 296(3):723-35. PubMed ID: 11181899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-glycoprotein (MDR1/ABCB1) and breast cancer resistance protein (BCRP/ABCG2) restrict brain accumulation of the JAK1/2 inhibitor, CYT387.
    Durmus S; Xu N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2013 Oct; 76():9-16. PubMed ID: 23827160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone.
    Kodaira H; Kusuhara H; Ushiki J; Fuse E; Sugiyama Y
    J Pharmacol Exp Ther; 2010 Jun; 333(3):788-96. PubMed ID: 20304939
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cloning and expression of murine sister of P-glycoprotein reveals a more discriminating transporter than MDR1/P-glycoprotein.
    Lecureur V; Sun D; Hargrove P; Schuetz EG; Kim RB; Lan LB; Schuetz JD
    Mol Pharmacol; 2000 Jan; 57(1):24-35. PubMed ID: 10617675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sestamibi is a substrate for MDR1 and MDR2 P-glycoprotein genes.
    Joseph B; Bhargava KK; Malhi H; Schilsky ML; Jain D; Palestro CJ; Gupta S
    Eur J Nucl Med Mol Imaging; 2003 Jul; 30(7):1024-31. PubMed ID: 12536246
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional induction of P-glycoprotein in the blood-brain barrier of streptozotocin-induced diabetic rats: evidence for the involvement of nuclear factor-kappaB, a nitrosative stress-sensitive transcription factor, in the regulation.
    Maeng HJ; Kim MH; Jin HE; Shin SM; Tsuruo T; Kim SG; Kim DD; Shim CK; Chung SJ
    Drug Metab Dispos; 2007 Nov; 35(11):1996-2005. PubMed ID: 17664251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain accumulation of the EML4-ALK inhibitor ceritinib is restricted by P-glycoprotein (P-GP/ABCB1) and breast cancer resistance protein (BCRP/ABCG2).
    Kort A; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Pharmacol Res; 2015 Dec; 102():200-7. PubMed ID: 26361725
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low systemic exposure of oral docetaxel in mice resulting from extensive first-pass metabolism is boosted by ritonavir.
    Bardelmeijer HA; Ouwehand M; Buckle T; Huisman MT; Schellens JH; Beijnen JH; van Tellingen O
    Cancer Res; 2002 Nov; 62(21):6158-64. PubMed ID: 12414642
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of P-glycoprotein and Bcrp at the rat blood-brain barrier following a subchronic morphine treatment is mediated through NMDA/COX-2 activation.
    Yousif S; Chaves C; Potin S; Margaill I; Scherrmann JM; Declèves X
    J Neurochem; 2012 Nov; 123(4):491-503. PubMed ID: 22845665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Poller B; Wagenaar E; Tang SC; Schinkel AH
    Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.